Chicago tries to close life expectancy gap
A new city campaign aims to close the whopping 11-year life expectancy gap between Black Chicagoans and their non-Black peers.
The big picture: As the city enters an era where its racial makeup is nearly 30% white, 30% Black and 30% Latino, Axios is starting a yearlong series examining racial equity in the city across several metrics from opportunities and perks to health disparities and disadvantages.
Backstory: The life expectancy gap wasn't always this big. In 2010, the disparity between Black and non-Black Chicagoans was 8.4 years.
In 2020, Black life expectancy in Chicago fell below 70 for the first time in decades, driven largely by COVID deaths.
During the pandemic in 2021, the gap peaked at 12.7 years before settling at 11.4 in 2022.
Across all races the average life expectancy is 77 years.
Driving the news: The "Healthy Chicago 2025 Strategic Plan" focuses on the root causes of health inequity including economics, housing and access to health care while zeroing in on the primary drivers of Black mortality, like chronic disease and opioid overdose, and the neighborhoods with the highest rates.
Zoom in: Chicago Department of Public Health is concentrating on these neighborhoods with a life expectancy much lower than the city's 77-year average.
What they're saying:"Preventing premature mortality from chronic diseases (namely heart disease), violence, and opioid overdose offer the most room for progress in reducing the racial life expectancy gap," CDPH commissioner Olusimbo Ige tells Axios.
"Reversing these trends will require consistent, long-term commitment to increase access and uptake of health protective behaviors and resources. We have already seen significant reductions in opioid overdose and violence, and we want to build on these successes."
The cost: While the report doesn't quote a specific cost of the program, it cites the use of hundreds of millions in funds for health-related projects including sports programs, alternative policing, homelessness services, prison re-entry programs and more.
Between the lines: Even before the pandemic, life expectancy in some largely Black neighborhoods was falling, in part, due to opioid deaths. Declines from 2010 to 2019 included:
Englewood: 3.3 years.
East Garfield Park 3.23 years.
Yes, but: COVID accelerated the drop further, seeing life expectancy declines from 2019 to 2020 of 5.84 years in West Garfield Park and 4.2 years in North Lawndale.
The intrigue: While Black communities saw an overall 4.6-year life expectancy drop from 2019 to 2020, Latinos saw the biggest decline of 6.3 years.
Most Black Chicagoans who died of COVID were people 70 years old and older, but at least 50% of Latino COVID deaths were in people aged 40-69, which CDPH attributes largely to a high representation among essential workers.
Here is how CDPH is trying to address the disparity by cause of death:
Chronic disease: Strategies include tobacco prevention and cessation programs through community partnerships.
Using the PlayStreets initiative to increase youth and adult physical activity.
Increasing healthy food access and navigation.
Increasing health literacy and promoting risk reduction resources.
Violence prevention: Strategies include "a proactive 2025 summer violence prevention plan."
Investing in community greenspace by cleaning vacant lots and promoting tree plantings.
Hospital-based violence interventions.
Opioid overdose reductions: Strategies include expanding access to treatment and recovery services and making overdose reversing drug Naloxone more available.
Surprising stat: In 2020, the opioid-related overdose death rate among Black males aged 45-64 years was six times higher than the rate among White males of the same age group.
Infectious disease: Strategies include modernizing public health surveillance systems and approaches to enhance rapid response.
Identifying highest-risk community areas.
Tailoring vaccine messaging for communities of color.
Promoting the uptake of the HIV services.
Infant and maternal health: Strategies include hyperlocal outreach to promote safe sleep practices.
Understanding barriers to prenatal care and creating a media campaign for improvement.
Modernizing the Women, Infants, and Children (WIC) program.
Mental health: Strategies include improving the city's Mental Health Equity Network and Crisis Assistance Response and Engagement program.
Developing "a housing to recovery continuum of care" for unhoused people and those with behavioral health conditions.
Federal effect: Ige acknowledges that Trump administration policies restricting funding for for equity-based work could affect federal support for the plan, but says, CDPH "intends to deploy programs and resources to serve the needs of Chicagoans with a priority on the people and places most impacted by adverse health outcomes."
What's next: CDPH says it should have updated life expectancy numbers this spring.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Chicago Tribune
32 minutes ago
- Chicago Tribune
New paper sheds light on experience of Black prisoners in infamous Stateville prison malaria experiments
Much has been said and written over the years about controversial malaria research conducted on inmates at Illinois' Stateville Penitentiary starting in the 1940s. But at least one part of that story has been largely ignored until now: the role of Black prisoners in that research, which helped lead to the modern practice of using genetic testing to understand how individual patients will react to certain medications, according to the authors of a newly published paper out of the University of Utah. 'We want to highlight the stories of Black prisoners that participated in this prison research in the 1950s onward and give them their due,' said Hannah Allen, a medical ethicist and assistant professor of philosophy at the University of Texas Rio Grande Valley, and first author of the paper, which was published as an opinion piece Wednesday in the Journal of the American Medical Association. 'They haven't been properly acknowledged in the past, and their participation in these studies was really foundational in launching the field of pharmacogenetics and, later on, precision medicine,' said Allen, who recently completed her doctorate at the University of Utah. Starting in the 1940s, researchers infected inmates at the Joliet-area prison with malaria to test the effectiveness of drugs to treat the illness as part of a U.S. military-funded effort to protect American troops overseas, according to the paper. A University of Chicago doctor was the principal investigator. The inmates consented to being part of the studies and were paid for their participation. At first, the research was greeted with enthusiasm. In 1945, Life magazine ran a spread about it, featuring a photo of a Stateville inmate with cups containing malaria-carrying mosquitoes pressed against his bare chest. The first line of the story reads, 'In three U.S. penitentiaries men who have been imprisoned as enemies of society are now helping science fight another enemy of society.' But as the years passed, attitudes began to shift. Questions arose about whether inmates could truly, freely consent to participate in medical experiments or whether they felt coerced into them because of their often dire circumstances. At the Nuremberg trials, defense attorneys for Nazi doctors introduced text and images from the Life article about Stateville prison, though an Illinois physician argued at the trials that the prisoners in Stateville consented to being part of medical research whereas Nazi prisoners did not, according to the JAMA paper. In the mid-1970s, news broke about a study at Tuskegee, in which Black men with syphilis went untreated for years — news that raised awareness of ethical problems in medical research. News outlets also began publishing more stories about prison research, according to the JAMA article. The Chicago Tribune published an article in 1973, in which an inmate participating in the Stateville malaria research said: 'I've been coerced into the project — for the money. Being here has nothing to do with 'doing good for mankind' … I didn't want to keep taking money from my family.' The experiments at Stateville came to a halt in the 1970s. A number of protections and regulations are now in place when it comes to research involving prisoners. Since the 1970s, the Stateville research has often been discussed and analyzed but little attention has been paid to its Black participants, said James Tabery, a medical ethicist and philosophy professor at the University of Utah who led the new research, which was funded by the federal National Institutes of Health. For a time, Black prisoners were excluded from the studies because of a myth that Black people were immune to malaria, Tabery said. Later on, once scientists had pinpointed the drug primaquine as an effective medication for malaria, they turned their attention to the question of why 5% to 10% of Black men experienced a violent reaction to the drug, according to the paper. Ultimately, the scientists were successful, finding that the adverse reaction was related to a specific genetic deficiency. 'There are people all over Chicago today that are getting tested, that clinicians are recommending they get a genetic test before they get prescribed a drug because they want to make sure that their patient isn't going to have an adverse reaction to the drug,' Tabery said. 'It's really sort of powerful and interesting that you can trace that approach to doing good clinical medicine right back to this particular moment and place and population.' But Tabery and Allen also found that the Black prisoners were not treated the same as the white prisoners who participated in research at Stateville. For one, they weren't paid as much as the white prisoners, the rationale being that the white prisoners were infected with malaria, whereas the Black prisoners were given the drug but not infected with the disease — though some of the Black prisoners got very ill after taking the medication, according to the paper. Also, researchers didn't protect the Black participants' privacy as well as they did for other participants. They published certain identifying information about the Black participants, such as initials, ages, heights and weights, whereas participants in the previous research were represented with case numbers, according to the paper. Researchers also recruited the Black prisoners' family members for the study, which they didn't do with earlier participants, according to the paper. 'You see them just doing things with the Black prisoners that they're not doing with the white prisoners,' Tabery said. Also, though scientists made an important discovery through the research on Black prisoners, the episode also highlights the difficulty that can occur in translating discoveries into real life help for patients. Though the World Health Organization now recommends genetic testing to protect people who are sensitive to antimalarials, many of the people who would benefit most from such testing still don't receive it because of financial barriers, supply chain issues and a lack of training, according to the paper. 'What we found is when you sort of shift to what was happening to the Black prisoners, these other lessons you hadn't thought of as being derivable from Stateville suddenly do become apparent,' Tabery said.
Yahoo
35 minutes ago
- Yahoo
History Shows the Danger of Trump's Health Policies
U.S. President Donald Trump and Health and Human Services Secretary Robert F. Kennedy Jr. attend an event in the East Room of the White House on May 22, 2025 in Washington, DC. Credit - Chip Somodevilla—Getty Images On May 11, 2023, President Joseph Biden ended the COVID-19 public health emergency, calling an finish to the pandemic. By the end of 2023, COVID-19 claimed the lives of over 20 million people around the world. But through international cooperation and evidence-based science, vaccines were developed and the world moved on. Indeed, perhaps the biggest success of the period was the quick production of a COVID-19 vaccine. The research behind the mRNA vaccine had been ongoing since the 1970s, but the emergency of the pandemic and international sharing of knowledge helped bring the vaccine to fruition. Today, the COVID-19 vaccine has been credited with saving 2.4 million lives around the world. But now, the U.S. is choosing competition over cooperation. With President Donald Trump's day one executive order to leave the World Health Organization (WHO)—blaming their COVID-19 response—and the shuttering of USAID, the country is taking steps towards further dividing health efforts across the globe. Here in the U.S., a sudden end to $11.4 billion of covid-related grants is stifling national pandemic preparedness efforts on the local and state levels. And most recently, Health and Human Services Secretary RFK Jr. purged experts from the CDC Advisory Committee, putting lives at risk. Historical lessons demonstrate the need for global health infrastructure that works together, shares knowledge, and remembers that pathogens do not stop at borders. White House's Pandemic Office, Busy With Bird Flu, May Shrink Under Trump One of the greatest global health achievements of all time—smallpox eradication—provides a perfect example of what can be done with independent scientific research and international cooperation. During the Cold War between the U.S. and USSR, decades of tension brought the world to the brink of nuclear war. Yet, incredibly, the nations managed to find common ground to support the efforts of smallpox eradication. Indeed, they understood the strategic benefits that came from letting public health practitioners and scientists work outside of political divides. The WHO was founded after World War II in 1948. Its formation marked a move from international health, that focused on nations, to global health, that would serve humanity first. The WHO's first eradication effort was the failed, U.S.-backed, Malaria Eradication Program from 1955 to 1969. The Smallpox Eradication Program, with intensive efforts beginning in 1967, provided a chance for redemption for the U.S. and WHO. For the United States, investing in disease eradication and poverty helped to mitigate growing backlash against the Vietnam War. In June of 1964, President Lyndon B. Johnson stated, 'I propose to dedicate this year to finding new techniques for making man's knowledge serve man's welfare.' He called for 1965—the same year he ordered ground troops to Vietnam to stop the spread of communism —to be a year of international cooperation that could bypass the politics of the Cold War. Previously, the USSR did not participate in the U.S. and WHO's first, failed global eradication plan for malaria. But upon rejoining the WHO in 1956, it was the Soviets who made the first call and investment into global eradication of smallpox in 1958. The WHO functioning as a mediator was crucial to allowing the USSR and the U.S. to work together. It allowed both nations to avoid giving credit to each other; rather success went to science itself. President Johnson called this 'a turning point' away from 'man against man' towards 'man against nature.' The limited role of politicians in the program proved to be key to its success. Scientists made decisions and worked together—no matter what country they came from—by focusing on disease and vaccination, not international tensions. The Soviet-initiated program was lead by Donald A. Henderson, a U.S. epidemiologist, who worked alongside the Russians until the last case of smallpox occurred in Somalia on October 26, 1977. During the 20th century, smallpox was responsible for an estimated 300 to 500 million deaths. Smallpox was officially declared eradicated by the WHO in October 1980, and is today still the only human disease to achieve this distinction. Less than a year after the declaration of smallpox eradication, the emergence of another pandemic, the HIV/AIDS crisis, reinforced the importance of science-first cooperation over politically-driven decision making. In June 1981, the first cases of a new unknown disease were reported in the CDC's Morbidity and Mortality Weekly Report. In short order, gay men were stigmatized and blamed in what would become one of the biggest public health disasters of all time. It took years of grassroots science-based activism to move beyond HIV/AIDS victim-blaming and find medical solutions. The Poster Child for AIDS Obscured as Much About the Crisis as He Revealed Too often, governments across the globe placed blame on the gay community for their 'sins' and did not provide needed support, leaving the sick to suffer and die. The pharmaceutical companies profited from the limited medications they had available and did not pursue sufficient development. The FDA process for new drugs was scheduled to take nine years, at a time when life expectancy after receiving an HIV/AIDS diagnosis was one year. These issues sparked activism, spawning the AIDS Coalition to Unleash Power (ACT UP) in 1987. ACT UP organizers took science into their own hands and began educating themselves. Members began reading scientific journals religiously, learning the chemistry and epidemiology of drug manufacturing and clinical trials. Members learned how to translate these dense scientific messages to educate the community members on what was—and what was not—being done to help. Because of this work, the FDA changed policies to allow for new treatments to be tested at accelerated rates in times of emergency. ACT UP was able to shift the cultural blame showing that the issue was a result of politics getting in the way of scientific advancements. By 1990, ACT UP influenced the largest federal HIV program to pass Congress, the Ryan White CARE Act. This program was a vital precursor to the 2003 PEPFAR (The U.S. President's Emergency Plan for AIDS Relief) global initiative. Both of these histories offer a powerful lesson: global health is national health, and national health is local health. With the recent funding cuts from the U.S. government, the future of global health is going in an unknown direction. And yet, the occurrence of pandemics is expected to increase in frequency due to climate change, mass migration, urbanization, and ecosystem destruction. It has been estimated that there is about a 25% chance we will have another COVID-sized pandemic within the next 10 years. No matter how secure the world makes borders, history shows that it can not protect us from disease if we do not have a strong, interconnected public health infrastructure. Luke Jorgensen is a Master of Public Health student at Purdue University where his epidemiology research examines human migration and infectious disease. Made by History takes readers beyond the headlines with articles written and edited by professional historians. Learn more about Made by History at TIME here. Opinions expressed do not necessarily reflect the views of TIME editors. Write to Made by History at madebyhistory@
The Hill
41 minutes ago
- The Hill
What to know about the new ‘Nimbus' COVID variant
The World Health Organization is keeping an eye on a new COVID-19 variant called NB.1.8.1, or 'Nimbus,' that has spread across Europe, the Americas and the Western Pacific. Nimbus is a descendant of the Omicron variant of the virus and was first identified in late January. Its spike mutations appear to make it more transmissible than other COVID variants, according to the WHO. Spike mutations refer to changes in spike proteins, which sit on the surface of the virus and help it enter healthy cells. While it is spreading in the U.S. and Canada, along with 20 other countries, it does not appear to be driving an increase in sickness or hospitalization. In April, NB.1.8.1 sequences made up 10.7 percent of all submitted sequences from confirmed COVID infections, up from 2.5 percent a month earlier, according to a risk evaluation released by the WHO. The WHO last month deemed NB.1.8.1 a variant 'under monitoring.' Here's what to know about the variant. Most cases of COVID-19 in the U.S. still stem from the LP.8.1 strain, another Omicron descendant. But it looks like NB.1.8.1 might soon replace it as the more common strain, according to data from the Centers for Disease Control and Prevention (CDC). The CDC estimates that 37 percent of COVID-19 cases in the U.S. stem from the NB.1.8.1 variant while 38 percent are a result from an infection of the LP.8.1 strain of the disease. At the end of May, the agency estimated that the NB.1.8.1 variant caused about 15 percent of all COVID cases. But the agency notes on its website that due to low numbers of virus sequences being reported, precision in the most recent reporting period is low. The NB.1.8.1 variant has been found in at least 13 states, according to Today, which cited data from the Global Initiative on Sharing All Influenza Data (GISAID) database. Those states are: California, New York, New Jersey, Maryland, Arizona, Illinois, Hawaii, Massachusetts, Ohio, Rhode Island, Vermont, Virginia and Washington. The available data on 'Nimbus' suggests that it poses a low global threat and that existing COVID-19 vaccines provide adequate protection against severe illness and hospitalization, according to the WHO. 'Currently approved COVID-19 vaccines are expected to remain effective to this variant against symptomatic and severe disease,' reads the WHO's risk evaluation. 'Despite a concurrent increase in cases and hospitalizations in some countries where NB.1.8.1 is widespread, current data do not indicate that this variant leads to more severe illness than other variants in circulation.' Lionel Gesh, an international consultant at the WHO, told The Hill that many new cases in Canada are likely linked to the NB.1.8.1 variant, but that there has not been any major changes in the country in terms of cases, hospitalizations, ICU admissions or deaths linked to COVID-19. Symptoms of NB.1.8.1 seem to be similar to those associated with other Omicron variants, according to Gresh. Some common COVID-19 symptoms include cough, fever, fatigue, muscle aches, congestion, headache, nausea, vomiting, and a new loss of smell or taste, according to the CDC. 'We should be as concerned about [NB.1.8.1] as we are concerned for COVID in general,' Gesh said. 'Not more, not less.' Some recent COVID-19 patients have reported experiencing something called 'razor blade throat,' according to Salon. But it is unclear if that symptom is connected to one of the COVID variants or another respiratory illness circulating, Ryan Gregory, an evolutionary and genome biologist at the University of Guelph in Canada, told the outlet.
